Aflibercept 8 mg cut RVO injections by up to 3 over 64 weeks in QUASAR, while a pair of additional posters show Amsler gaps in AMD and BRAO-linked stroke risk.
Kwaku Osei, OD, PhD, FAAO, discussed patient-reported outcomes with a senofilcon C (Johnson & Johnson; Acuvue Vita), reusable lens, with the majority of wearers rating comfort, vision, and handling favorably.
Andrew Pucker, OD, PhD, FAAO, FSLS, FBCLA, discussed how oculomics research presented at AAOpt 2026 could eventually support point-of-care diagnosis and referral decisions.